<1%, postmarketing, and/or case reports: Nephrolithiasis (with consumption of large quantities) Warnings/Precautions Gastrointestinal: Nausea, stomach pain, vomiting Possible color interference with determination of 5-HIAA and VMA discontinue for 48 hours prior to test Adverse ReactionsĬentral nervous system: Dizziness, drowsiness, headache There are no known significant interactions. Store at room temperature do not refrigerate. Some products may contain phenylalanine and/or sodium. Granules: Empty contents of packet onto tongue and swallow for best taste, do not chew granules. Oral: Administer with a large quantity of fluid to ensure proper action.Įxtended-release tablet: Do not break, crush, or chew extended-release tablet. Note: Safety and efficacy for the use of cough and cold products in infants and young children is limited the AAP warns against the use of these products for respiratory illnesses in infants and young children the FDA does not recommend OTC use in infants and children <2 years of age due to the risk of serious and life-threatening adverse effects (including death) and recommends to use with caution in pediatric patients ≥2 years of age (AAP 20)Ĭhildren 2 years to <4 years: Limited data available: 50 to 100 mg every 4 hours as needed do not exceed 6 doses in 24 hours (Kliegman 2007)Ĭhildren 4 years to <6 years: 50 to 100 mg every 4 hours as needed do not exceed 6 doses in 24 hours.Ĭhildren 6 years to <12 years: 100 to 200 mg every 4 hours as needed do not exceed 6 doses in 24 hoursĬhildren ≥12 years and Adolescents: 200 to 400 mg every 4 hours as needed do not exceed 6 doses in 24 hoursĬhildren 4 years to <6 years: 100 mg every 4 hours as needed do not exceed 6 doses in 24 hoursĬhildren 6 years to <12 years: 200 mg every 4 hours as needed do not exceed 6 doses in 24 hoursĬhildren ≥12 years and Adolescents: 400 mg every 4 hours as needed do not exceed 6 doses in 24 hoursĮxtended release tablet: Children ≥12 years and Adolescents: 600 mg to 1,200 mg every 12 hours as needed do not exceed 2 doses nor 2,400 mg in 24 hours Administration Liquid: 200 to 400 mg every 4 hours as needed maximum: 2,400 mg/24 hours Dosing: Geriatric Immediate-release tablet: 200 to 400 mg every 4 hours as needed maximum: 2,400 mg/24 hours Granules: 200 to 400 mg every 4 hours as needed maximum: 2,400 mg/24 hoursĮxtended-release tablet: 600 mg to 1,200 mg every 12 hours as needed maximum: 2,400 mg/24 hours OTC labeling: When used for self-medication, do not use extended-release tablets in children <12 years. Pharmacokinetics/Pharmacodynamics AbsorptionĬough (expectorant): Help loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive Contraindications Possible mechanisms include a central antitussive effect, or a peripheral effect by increased sputum volume serving as a barrier shielding cough receptors within the respiratory epithelium from the tussive stimulus (Dicpinigaitis 2003). Guaifenesin inhibits cough reflex sensitivity in subjects with upper respiratory tract infections whose cough receptors are transiently hypersensitive, but not in healthy volunteers. Thought to act as expectorant by increasing the effective hydration of the respiratory tract, maintains the sol layer needed for ciliary clearance and reduces the viscosity of respiratory mucus, thereby further facilitating its removal by natural clearance processes. Tussin Mucus & Chest Congest: 100 mg/5 mL (118 mL) Robitussin Mucus+Chest Congest: 100 mg/5 mL (118 mL) Robafen Mucus/Chest Congestion: 200 mg/10 mL (118 mL) Mucus Relief Childrens: 100 mg/5 mL (118 mL ) Mucinex Chest Congestion Child: 100 mg/5 mL (118 mL ) = Discontinued productīuckleys Chest Congestion: 100 mg/5 mL (118 mL) ĭiabetic Siltussin DAS-Na: 100 mg/5 mL (118 mL ) ĭiabetic Tussin: 100 mg/5 mL (118 mL) Excipient information presented when available (limited, particularly for generics) consult specific product labeling.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |